ADVFN US – Market Content Editor
-

U.S. Stocks Fluctuate After Early Advance But Close Mostly Higher
Stocks fluctuated over the course of the trading session on Tuesday after an early move to the upside but largely maintained a positive bias. The major averages all ended the day in positive territory, regaining ground following the pullback seen during Monday’s trading. The tech-heavy Nasdaq advanced 137.75 points or 0.6 percent to 23,413.67, the…
-

Amazon unveils powerful new Trainium3 AI chip and hints at Nvidia-compatible Trainium4
Amazon Web Services (NASDAQ:AMZN), which has spent several years designing its own silicon for AI training, rolled out the latest generation of its accelerator lineup on Tuesday: Trainium3, a major step forward in performance and efficiency for large-scale AI workloads. The announcement came during AWS re:Invent 2025, where the cloud giant also previewed the next…
-

Eventbrite Shares Skyrocket After Agreeing to $500 Million Sale to Bending Spoons
Eventbrite Inc. (NYSE:EB) surged 78.6% in premarket trading on Tuesday after revealing it has signed a definitive agreement to be acquired by Bending Spoons in an all-cash deal worth roughly $500 million. According to the terms outlined in the announcement, Eventbrite shareholders will receive $4.50 per share in cash, an offer that represents an 82%…
-

Scholastic Shares Jump After Striking Deals to Sell Headquarters and Distribution Hub for $401 Million
Scholastic Corporation (NASDAQ:SCHL) rallied 5.2% in Tuesday’s premarket session after revealing that it has reached binding agreements to sell both its New York City headquarters and its Missouri distribution center through sale-leaseback arrangements expected to generate $401 million in net proceeds. The children’s publishing giant announced that it will sell its historic 555–557 Broadway headquarters…
-

Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program
Tiziana Life Sciences Ltd (NASDAQ:TLSA) slid 7.8% in premarket trading on Tuesday after announcing that it intends to separate its anti-IL-6 receptor monoclonal antibody, TZLS-501, into an independently listed public company. According to Tiziana, the move aims to “enhance the strategic focus of each company and to drive value for shareholders.” Investors on a to-be-determined…
-

Blackbaud Shares Climb on Anthropic Collaboration and Bigger Buyback Authorization
Blackbaud (NASDAQ:BLKB) jumped 5.3% in premarket trading Tuesday after unveiling a new partnership with Anthropic and announcing a major expansion of its share repurchase program. The Charleston-based software firm, known for its tools serving nonprofits and social impact organizations, said it will supply the fundraising connector for Claude for Nonprofits. The integration links Blackbaud’s data…
-

Token Cat Shares Jump After Board Approves $1 Billion Crypto Investment Strategy
Token Cat Limited (NASDAQ:TC) climbed 4.1% in Tuesday’s premarket session after the company unveiled a major strategic shift: its board has signed off on a Crypto Asset Investment Policy that will allow up to $1 billion of its cash reserves to be deployed into select digital assets. According to the announcement, Token Cat intends to…
-

Gilat Shares Gain After Securing $10 Million Contract for Earth Observation Solution
Gilat Satellite Networks Ltd. (NASDAQ:GILT) saw its stock rise 3.4% on Tuesday after the company revealed it has won a contract valued at roughly $10 million to supply a tailored Earth Observation Solution. The project, scheduled for delivery over the next year, marks a strategic push for Gilat as it broadens its capabilities beyond traditional…
-

enGene Shares Rise After FDA Taps Bladder Cancer Therapy for CMC Pilot
enGene Holdings Inc. (NASDAQ:ENGN) traded 2% higher on Tuesday after the company revealed that the FDA has selected its bladder cancer therapy for a specialized program aimed at accelerating manufacturing readiness. The gene-medicine developer announced that its lead non-viral gene therapy candidate, detalimogene voraplasmid, has been accepted into the FDA’s Chemistry, Manufacturing, and Controls (CMC)…
-

Silexion Shares Decline After Update on German Regulatory Review
Silexion Therapeutics Corp (NASDAQ:SLXN) slipped 4% in Tuesday’s premarket session after the biotech firm announced it received written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) concerning its planned Phase 2/3 study for SIL204. The RNA interference drug developer characterized the guidance as both “positive” and “an important milestone,” signaling regulatory…